RxDoctor Payments Data

Christina Heidenberger, PA

Medical · St Petersburg, FLNPI 1912211418

Payments from drug & device makers

$4,722in general payments, 2019–2025

Across 180 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$647
  • Endo Pharmaceuticals Inc.$620
  • Astellas Pharma US Inc$605
  • Procept Biorobotics Corporation$432
  • Sumitomo Pharma America, Inc.$328
  • Teleflex LLC$249
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,58297%
  • Education$1403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,722 in reported general payments places this provider in the 85th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$56,913
Medicare patients
358
Services billed
9,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron179$126,652
MyrbetriqMirabegron169$117,775
Mirabegron ErMirabegron12$8,298
Fesoterodine Fumarate ErFesoterodine Fumarate41$5,094
Methenamine Hippurate51$4,154
Testosterone Cypionate88$3,932
Solifenacin Succinate56$3,330
Tamsulosin Hcl301$3,215
Testosterone18$2,422
Trospium Chloride ErTrospium Chloride17$1,708
CefuroximeCefuroxime Axetil107$1,225
Alfuzosin Hcl ErAlfuzosin Hcl46$986
Estradiol17$940
Oxybutynin Chloride ErOxybutynin Chloride53$912
Oxybutynin Chloride42$822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$328$126,652179 claims
Astellas Pharma US IncMyrbetriq$605$117,775169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,031 medical providers in Florida.

Other medical in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →